About This Study
Graft-versus-host disease happens when the new cells from a stem cell transplant attack the patient's own body cells. This study aims to learn more about a new medicine called ruxolitinib to prevent this disease after a stem cell transplant. We will compare this medicine to the standard treatment. Volunteers must be planning to undergo a stem cell transplant for leukemia or lymphoma. The study team will provide more information.
What Activities Are a Part of this Study?
- Informed Consent Review
- Use of Study Treatments or Placebo
- After Study Follow-Up Activities
- Review of Medical History
- Physical Examinations
- Phone Calls and/or Emails
- Study Visits and Consultations
- Surveys/Questionnaires
- Laboratory and Imaging Tests
- Specimen Sample Collection
Age & Gender
- 18 - 100 years old
- All Genders
Language
- This study enrolls English and Spanish speakers
Additional Study Information
- Compensation Offered
- No reimbursement offered
Study Locations
- Greater Charlotte, NC